- Home
- RMCF vs CLDI Comparison
RMCF vs CLDI Comparison
Compare RMCF & CLDI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RMCF
- CLDI
- Stock Information
- Founded
- RMCF 1981
- CLDI 2014
- Country
- RMCF United States
- CLDI United States
- Employees
- RMCF N/A
- CLDI N/A
- Industry
- RMCF Specialty Foods
- CLDI Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- RMCF Consumer Staples
- CLDI Health Care
- Exchange
- RMCF Nasdaq
- CLDI Nasdaq
- Market Cap
- RMCF 11.4M
- CLDI 9.9M
- IPO Year
- RMCF N/A
- CLDI N/A
- Fundamental
- Price
- RMCF $1.62
- CLDI $1.36
- Analyst Decision
- RMCF
- CLDI
- Analyst Count
- RMCF 0
- CLDI 0
- Target Price
- RMCF N/A
- CLDI N/A
- AVG Volume (30 Days)
- RMCF 47.9K
- CLDI 235.2K
- Earning Date
- RMCF 01-13-2026
- CLDI 11-13-2025
- Dividend Yield
- RMCF N/A
- CLDI N/A
- EPS Growth
- RMCF N/A
- CLDI N/A
- EPS
- RMCF N/A
- CLDI N/A
- Revenue
- RMCF $29,988,000.00
- CLDI N/A
- Revenue This Year
- RMCF N/A
- CLDI N/A
- Revenue Next Year
- RMCF N/A
- CLDI N/A
- P/E Ratio
- RMCF N/A
- CLDI N/A
- Revenue Growth
- RMCF 8.09
- CLDI N/A
- 52 Week Low
- RMCF $1.12
- CLDI $1.10
- 52 Week High
- RMCF $3.18
- CLDI $27.63
- Technical
- Relative Strength Index (RSI)
- RMCF 53.68
- CLDI 38.89
- Support Level
- RMCF $1.36
- CLDI $1.29
- Resistance Level
- RMCF $1.66
- CLDI $1.56
- Average True Range (ATR)
- RMCF 0.11
- CLDI 0.13
- MACD
- RMCF 0.00
- CLDI -0.01
- Stochastic Oscillator
- RMCF 84.88
- CLDI 42.37
About RMCF Rocky Mountain Chocolate Factory Inc.
Rocky Mountain Chocolate Factory Inc operates as a manufacturer of chocolate candies and confectionery products. The business activity of the firm functions through Franchising, Manufacturing, Retail Stores, U-Swirl Operations, and Other t. The products of the company include varieties of Clusters, Caramels, Creams, Toffees, Mints, and Truffles.
About CLDI Calidi Biotherapeutics Inc.
Calidi Biotherapeutics Inc is a clinical-stage immuno-oncology company with technology designed to arm the immune system to fight cancer. The Company's stem cell-based platforms utilize potent allogeneic stem cells capable of carrying payloads of oncolytic viruses for use in a many oncology indications, including high-grade gliomas and solid tumors. Its products include CLD-101 for Recurrent HGG; CLD-201 for Solid Tumors, and CLD-400 for certain lung cancer and Metastatic Solid Tumors. In addition to its pipeline products, the Company's is also engaged in discovery research of CLD-301 (AAA) for tumor Indications.